Overview Performance Dividends Peer Group Options

(ACRS) Aclaris Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00461U1051

Inflammatory, Dermatology, Respiratory, Autoimmune, Oncology

ACRS EPS (Earnings per Share)

EPS (Earnings per Share) of ACRS over the last years for every Quarter: "2020-03": -0.37, "2020-06": -0.28, "2020-09": -0.25, "2020-12": -0.3, "2021-03": -0.57, "2021-06": -0.34, "2021-09": -0.35, "2021-12": -0.37, "2022-03": -0.28, "2022-06": -0.25, "2022-09": -0.32, "2022-12": -0.5, "2023-03": -0.39, "2023-06": -0.42, "2023-09": -0.41, "2023-12": -0.02, "2024-03": -0.24, "2024-06": -0.15, "2024-09": -0.11, "2024-12": -1.01, "2025-03": -0.12,
EPS Growth (4Y CAGR): 22.92%
EPS Growth Momentum (3Y): 37.5%

ACRS Revenue

Revenue of ACRS over the last years for every Quarter: 2020-03: 1.407, 2020-06: 2.046, 2020-09: 1.449, 2020-12: 1.58, 2021-03: 1.777, 2021-06: 1.824, 2021-09: 1.659, 2021-12: 1.501, 2022-03: 1.453, 2022-06: 1.528, 2022-09: 19.018, 2022-12: 7.753, 2023-03: 2.528, 2023-06: 1.869, 2023-09: 9.282, 2023-12: 17.57, 2024-03: 2.398, 2024-06: 2.766, 2024-09: 4.346, 2024-12: 9.211, 2025-03: 1.455,
Revenue Growth (4Y CAGR): -5.49%
Revenue Trend (4Y Correlation): 30.0%
Revenue Growth Momentum (3Y): -53.3%

Description: ACRS Aclaris Therapeutics

Aclaris Therapeutics Inc (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company developing novel therapeutics for immune-inflammatory diseases, operating through Therapeutics and Contract Research segments. The company focuses on addressing unmet needs in immuno-inflammatory diseases, with a pipeline of promising candidates.

The Therapeutics segment is driving the companys growth, with a diverse portfolio of assets targeting various conditions, including atopic dermatitis, asthma, and autoimmune diseases. Key assets include ATI-1777, a soft JAK1/3 inhibitor in Phase 2b, and Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a. Other notable candidates are ATI-2138, Zunsemetinib (ATI-450), and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stages.

Analyzing the , ACRS is currently trading at $1.18, below its SMA20 ($1.26) and SMA50 ($1.41), indicating a short-term downtrend. The stocks ATR is 0.11, representing 9.19% volatility. Considering the , ACRS has a market capitalization of $132.10M and a negative P/E ratio, indicating significant losses. The companys RoE is -92.41%, highlighting the substantial losses incurred.

Combining and , a forecast for ACRS can be derived. The stocks current price is near its 52W Low ($1.01), and the SMA200 ($1.90) is significantly higher, indicating potential support. However, the negative P/E ratio and high RoE losses suggest that the companys financials need improvement. A potential catalyst for growth could be positive trial results or strategic partnerships. Assuming successful trial outcomes, ACRS could potentially reach $2.50-$3.50, representing a 100%-200% increase from current levels. However, this is contingent upon the companys ability to address its financial challenges and deliver on its pipeline promises.

To mitigate potential risks, investors should closely monitor ACRSs cash burn rate, trial results, and any potential partnerships or collaborations. A thorough analysis of the companys financials and pipeline progress is essential to making an informed investment decision.

Additional Sources for ACRS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

ACRS Stock Overview

Market Cap in USD 156m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2015-10-07

ACRS Stock Ratings

Growth Rating -23.4
Fundamental -
Dividend Rating 0.0
Rel. Strength 32.1
Analysts 4.33 of 5
Fair Price Momentum 1.27 USD
Fair Price DCF -

ACRS Dividends

Currently no dividends paid

ACRS Growth Ratios

Growth Correlation 3m 80.1%
Growth Correlation 12m 21.1%
Growth Correlation 5y -63.6%
CAGR 5y -4.39%
CAGR/Max DD 5y -0.04
Sharpe Ratio 12m -0.51
Alpha 7.53
Beta 1.551
Volatility 74.69%
Current Volume 1282.5k
Average Volume 20d 726k
Stop Loss 1.5 (-5.7%)
What is the price of ACRS shares?
As of July 12, 2025, the stock is trading at USD 1.59 with a total of 1,282,522 shares traded.
Over the past week, the price has changed by +10.42%, over one month by +5.30%, over three months by +47.22% and over the past year by +25.20%.
Is Aclaris Therapeutics a good stock to buy?
Neither. Based on ValueRay´s Analyses, Aclaris Therapeutics is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -23.35 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACRS is around 1.27 USD . This means that ACRS is currently overvalued and has a potential downside of -20.13%.
Is ACRS a buy, sell or hold?
Aclaris Therapeutics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ACRS.
  • Strong Buy: 3
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for ACRS share price target?
According to our own proprietary Forecast Model, ACRS Aclaris Therapeutics will be worth about 1.5 in July 2026. The stock is currently trading at 1.59. This means that the stock has a potential downside of -4.4%.
Issuer Target Up/Down from current
Wallstreet Target Price 8.2 413.8%
Analysts Target Price 8.2 415.7%
ValueRay Target Price 1.5 -4.4%